BioMarin Pharmaceutical (BMRN) Stock Forecast, Price Target & Predictions
BMRN Stock Forecast
BioMarin Pharmaceutical stock forecast is as follows: an average price target of $111.41 (represents a 31.22% upside from BMRN’s last price of $84.90) and a rating consensus of 'Buy', based on 17 wall street analysts offering a 1-year stock forecast.
BMRN Price Target
The average price target for BioMarin Pharmaceutical (BMRN) is $111.41 based on 1-year price targets from 17 Wall Street analysts in the past 3 months, with a price target range of $135.00 to $72.00. This represents a potential 31.22% upside from BMRN's last price of $84.90.
BMRN Analyst Ratings
According to 17 Wall Street analysts, BioMarin Pharmaceutical's rating consensus is 'Buy'. The analyst rating breakdown for BMRN stock is 0 'Strong Buy' (0.00%), 10 'Buy' (58.82%), 7 'Hold' (41.18%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
BioMarin Pharmaceutical Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 05, 2024 | Christopher Raymond | Raymond James | $122.00 | $86.74 | 40.65% | 43.70% |
| Sep 05, 2024 | George Farmer | Scotiabank | $95.00 | $86.75 | 9.51% | 11.90% |
| Aug 27, 2024 | Christopher Raymond | Raymond James | $107.00 | $88.69 | 20.64% | 26.03% |
| Aug 21, 2024 | Paul Matteis | Stifel Nicolaus | $115.00 | $93.84 | 22.55% | 35.45% |
| Aug 20, 2024 | William Pickering | Tudor Pickering | $110.00 | $94.20 | 16.77% | 29.56% |
| Aug 06, 2024 | Paul Matteis | Stifel Nicolaus | $112.00 | $85.98 | 30.26% | 31.92% |
| Aug 06, 2024 | Cory Kasimov | Evercore ISI | $115.00 | $85.98 | 33.74% | 35.45% |
| Aug 06, 2024 | Whitney Ijem | Canaccord Genuity | $93.00 | $80.47 | 15.57% | 9.54% |
| Jun 27, 2024 | Mohit Bansal | Wells Fargo | $115.00 | $85.25 | 34.90% | 35.45% |
| Jun 04, 2024 | William Pickering | Tudor Pickering | $91.00 | $78.87 | 15.38% | 7.18% |
The latest BioMarin Pharmaceutical stock forecast, released on Sep 05, 2024 by Christopher Raymond from Raymond James, set a price target of $122.00, which represents a 40.65% increase from the stock price at the time of the forecast ($86.74), and a 43.70% increase from BMRN last price ($84.90).
BioMarin Pharmaceutical Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 5 | 9 | 14 |
| Avg Price Target | $109.80 | $109.33 | $104.57 |
| Last Closing Price | $84.90 | $84.90 | $84.90 |
| Upside/Downside | 29.33% | 28.78% | 23.17% |
In the current month, the average price target of BioMarin Pharmaceutical stock is $109.80, according to 5 Wall Street analysts offering twelve months forecast. The average price target represents a 29.33% increase as opposed to BioMarin Pharmaceutical's last price of $84.90. This month's average price target is up 0.43% compared to last quarter, and up 5.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 13, 2024 | Canaccord Genuity | Hold | Hold | Hold |
| Sep 05, 2024 | Stifel Nicolaus | Underperform | Underperform | Hold |
| Sep 05, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Sep 05, 2024 | Scotiabank | Sector Perform | Sector Perform | Hold |
| Sep 04, 2024 | Cantor Fitzgerald | Overweight | Overweight | Hold |
| Aug 27, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 20, 2024 | Scotiabank | Underperform | Underperform | Hold |
| Aug 20, 2024 | Wells Fargo | Sector Perform | Sector Perform | Hold |
| Aug 20, 2024 | Bernstein | Market Perform | Outperform | Upgrade |
| Aug 06, 2024 | William Blair | Outperform | Outperform | Hold |
BioMarin Pharmaceutical's last stock rating was published by Canaccord Genuity on Sep 13, 2024. The company gave BMRN a "Hold" rating, the same as its previous rate.
BioMarin Pharmaceutical Financial Forecast
BioMarin Pharmaceutical Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $646.21B | $581.33B | $595.27M | $596.41M | $537.54M | $505.34M | $533.80M | $519.36M | $449.81M | $408.74M | $501.69M | $486.07M | $452.12M | $476.78M | $429.49M | $502.07M | $454.44M | $461.10M |
| Avg Forecast | $928.27M | $905.93M | $883.63M | $857.95M | $812.80M | $780.63M | $766.73M | $740.15M | $736.56M | $704.27M | $663.98M | $651.83M | $638.82M | $603.84M | $595.23M | $570.35M | $537.62M | $518.45M | $520.20M | $510.95M | $442.38M | $435.30M | $448.31M | $446.35M | $439.33M | $457.38M | $418.62M | $468.58M | $457.91M | $455.76M |
| High Forecast | $954.22M | $931.25M | $908.32M | $881.92M | $835.51M | $802.45M | $788.16M | $760.84M | $757.15M | $721.31M | $682.53M | $670.04M | $663.25M | $660.00M | $611.87M | $586.29M | $552.64M | $532.94M | $536.62M | $527.09M | $456.35M | $449.04M | $462.46M | $460.44M | $453.20M | $471.82M | $431.83M | $483.37M | $472.36M | $470.15M |
| Low Forecast | $886.13M | $864.80M | $843.52M | $819.00M | $775.90M | $745.19M | $731.93M | $706.55M | $703.13M | $687.60M | $633.84M | $622.23M | $625.52M | $573.53M | $568.21M | $544.46M | $513.21M | $494.92M | $498.44M | $489.59M | $423.88M | $417.10M | $429.56M | $427.68M | $420.95M | $438.25M | $401.11M | $448.99M | $438.76M | $436.70M |
| # Analysts | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 13 | 16 | 8 | 6 | 12 | 19 | 18 | 9 | 8 | 8 | 11 | 15 | 17 | 9 | 9 | 10 | 11 | 7 | 7 | 9 | 8 | 6 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1011.57% | 962.72% | 1.00% | 1.05% | 1.00% | 0.97% | 1.03% | 1.02% | 1.02% | 0.94% | 1.12% | 1.09% | 1.03% | 1.04% | 1.03% | 1.07% | 0.99% | 1.01% |
BioMarin Pharmaceutical's average Quarter revenue forecast for Mar 24 based on 6 analysts is $651.83M, with a low forecast of $622.23M, and a high forecast of $670.04M. BMRN's average Quarter revenue forecast represents a -99.90% decrease compared to the company's last Quarter revenue of $646.21B (Dec 23).
BioMarin Pharmaceutical EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 13 | 16 | 8 | 6 | 12 | 19 | 18 | 9 | 8 | 8 | 11 | 15 | 17 | 9 | 9 | 10 | 11 | 7 | 7 | 9 | 8 | 6 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $14.22B | $25.66B | $99.98M | $86.88M | $10.62M | $27.58M | $63.98M | $57.34M | $-37.34M | $-15.45M | $45.06M | $55.02M | $-8.08M | $-24.98M | $-9.53M | $134.23M | $22.43M | $42.99M |
| Avg Forecast | $36.06M | $35.19M | $34.32M | $33.32M | $31.57M | $30.32M | $29.78M | $28.75M | $28.61M | $27.36M | $25.79M | $261.07M | $24.81M | $23.45M | $23.12M | $237.34M | $20.88M | $-20.40M | $20.21M | $253.84M | $17.18M | $16.91M | $17.41M | $162.69M | $17.06M | $17.77M | $16.26M | $18.20M | $17.79M | $17.70M |
| High Forecast | $37.06M | $36.17M | $35.28M | $34.26M | $32.45M | $31.17M | $30.61M | $29.55M | $29.41M | $28.02M | $26.51M | $313.29M | $25.76M | $25.64M | $23.77M | $284.81M | $21.47M | $-16.32M | $20.84M | $304.61M | $17.73M | $17.44M | $17.96M | $195.22M | $17.60M | $18.33M | $16.77M | $18.78M | $18.35M | $18.26M |
| Low Forecast | $34.42M | $33.59M | $32.76M | $31.81M | $30.14M | $28.94M | $28.43M | $27.44M | $27.31M | $26.71M | $24.62M | $208.86M | $24.30M | $22.28M | $22.07M | $189.87M | $19.93M | $-24.47M | $19.36M | $203.07M | $16.46M | $16.20M | $16.69M | $130.15M | $16.35M | $17.02M | $15.58M | $17.44M | $17.04M | $16.96M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 573.05% | 1094.08% | 4.32% | 0.37% | 0.51% | -1.35% | 3.17% | 0.23% | -2.17% | -0.91% | 2.59% | 0.34% | -0.47% | -1.41% | -0.59% | 7.38% | 1.26% | 2.43% |
6 analysts predict BMRN's average Quarter EBITDA for Mar 24 to be $261.07M, with a high of $313.29M and a low of $208.86M. This is -98.16% lower than BioMarin Pharmaceutical's previous annual EBITDA (Dec 23) of $14.22B.
BioMarin Pharmaceutical Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 13 | 16 | 8 | 6 | 12 | 19 | 18 | 9 | 8 | 8 | 11 | 15 | 17 | 9 | 9 | 10 | 11 | 7 | 7 | 9 | 8 | 6 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $20.38B | $40.38B | $56.04M | $50.85M | $-249.00K | $-6.65M | $27.66M | $120.80M | $-57.90M | $-36.49M | $12.94M | $17.37M | $22.10M | $784.80M | $-29.18M | $81.38M | $15.02M | $55.04M |
| Avg Forecast | - | - | - | - | $150.88M | $136.65M | $137.18M | $124.93M | $117.72M | $106.76M | $71.74M | $190.75M | $39.53M | $44.02M | $42.38M | $173.41M | $-11.70M | $-48.17M | $6.60M | $185.46M | $-72.68M | $-50.14M | $-21.89M | $51.37M | $-33.71M | $50.13M | $-22.58M | $498.05M | $-7.32M | $11.82M |
| High Forecast | - | - | - | - | $156.36M | $141.61M | $142.16M | $129.47M | $122.00M | $127.03M | $74.35M | $228.90M | $52.11M | $74.03M | $43.92M | $208.09M | $-11.01M | $-38.54M | $6.87M | $222.55M | $-68.73M | $-47.41M | $-20.70M | $61.64M | $-31.88M | $52.18M | $-21.36M | $597.66M | $-6.92M | $12.30M |
| Low Forecast | - | - | - | - | $141.98M | $128.59M | $129.08M | $117.56M | $110.78M | $95.95M | $67.51M | $152.60M | $35.04M | $24.01M | $39.88M | $138.72M | $-12.12M | $-57.81M | $6.24M | $148.37M | $-75.67M | $-52.19M | $-22.78M | $41.09M | $-35.09M | $47.40M | $-23.51M | $398.44M | $-7.62M | $11.18M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 515.41% | 917.29% | 1.32% | 0.29% | 0.02% | 0.14% | 4.19% | 0.65% | 0.80% | 0.73% | -0.59% | 0.34% | -0.66% | 15.66% | 1.29% | 0.16% | -2.05% | 4.66% |
BioMarin Pharmaceutical's average Quarter net income forecast for Mar 24 is $190.75M, with a range of $152.60M to $228.90M. BMRN's average Quarter net income forecast represents a -99.06% decrease compared to the company's last Quarter net income of $20.38B (Dec 23).
BioMarin Pharmaceutical SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 13 | 16 | 8 | 6 | 12 | 19 | 18 | 9 | 8 | 8 | 11 | 15 | 17 | 9 | 9 | 10 | 11 | 7 | 7 | 9 | 8 | 6 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $275.02B | $223.93B | $215.34M | $223.00M | $245.74M | $216.82M | $196.84M | $194.62M | $217.60M | $183.30M | $184.20M | $174.30M | $195.54M | $179.45M | $175.40M | $202.97M | $204.89M | $187.18M |
| Avg Forecast | $371.77M | $362.82M | $353.89M | $343.60M | $325.52M | $312.64M | $307.07M | $296.43M | $294.99M | $282.06M | $265.92M | $307.31M | $255.84M | $241.83M | $238.39M | $279.38M | $215.31M | $241.96M | $208.34M | $298.80M | $177.17M | $174.34M | $179.55M | $178.76M | $175.95M | $183.18M | $167.65M | $187.66M | $183.39M | $182.53M |
| High Forecast | $382.16M | $372.96M | $363.78M | $353.20M | $334.62M | $321.38M | $315.65M | $304.71M | $303.23M | $288.88M | $273.35M | $368.78M | $265.63M | $264.33M | $245.05M | $335.25M | $221.33M | $290.35M | $214.91M | $358.56M | $182.77M | $179.84M | $185.21M | $184.40M | $181.50M | $188.96M | $172.95M | $193.59M | $189.18M | $188.29M |
| Low Forecast | $354.89M | $346.35M | $337.82M | $328.00M | $310.74M | $298.45M | $293.13M | $282.97M | $281.60M | $275.38M | $253.85M | $245.85M | $250.52M | $229.70M | $227.57M | $223.50M | $205.54M | $193.56M | $199.62M | $239.04M | $169.76M | $167.04M | $172.04M | $171.28M | $168.59M | $175.52M | $160.64M | $179.82M | $175.72M | $174.90M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1074.97% | 925.96% | 0.90% | 0.80% | 1.14% | 0.90% | 0.94% | 0.65% | 1.23% | 1.05% | 1.03% | 0.98% | 1.11% | 0.98% | 1.05% | 1.08% | 1.12% | 1.03% |
BioMarin Pharmaceutical's average Quarter SG&A projection for Mar 24 is $307.31M, based on 6 Wall Street analysts, with a range of $245.85M to $368.78M. The forecast indicates a -99.89% fall compared to BMRN last annual SG&A of $275.02B (Dec 23).
BioMarin Pharmaceutical EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 13 | 16 | 8 | 6 | 12 | 19 | 18 | 9 | 8 | 8 | 11 | 15 | 17 | 9 | 9 | 10 | 11 | 7 | 7 | 9 | 8 | 6 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $0.11 | $214.53 | $0.30 | $0.27 | $-0.00 | $-0.04 | $0.15 | $0.66 | $-0.32 | $-0.20 | $0.07 | $0.10 | $0.12 | $4.33 | $-0.16 | $0.45 | $0.08 | $0.31 |
| Avg Forecast | - | - | - | - | $0.75 | $0.68 | $0.68 | $0.62 | $0.59 | $0.53 | $0.36 | $0.31 | $0.20 | $0.22 | $0.21 | $0.16 | $-0.06 | $-0.01 | $0.03 | $0.21 | $-0.36 | $-0.25 | $-0.11 | $-0.09 | $-0.17 | $0.25 | $-0.11 | $0.03 | $-0.04 | $0.06 |
| High Forecast | - | - | - | - | $0.78 | $0.71 | $0.71 | $0.65 | $0.61 | $0.63 | $0.37 | $0.32 | $0.26 | $0.37 | $0.22 | $0.16 | $-0.05 | $-0.01 | $0.03 | $0.22 | $-0.34 | $-0.24 | $-0.10 | $-0.08 | $-0.16 | $0.26 | $-0.11 | $0.03 | $-0.03 | $0.06 |
| Low Forecast | - | - | - | - | $0.71 | $0.64 | $0.64 | $0.59 | $0.55 | $0.48 | $0.34 | $0.29 | $0.17 | $0.12 | $0.20 | $0.15 | $-0.06 | $-0.01 | $0.03 | $0.20 | $-0.38 | $-0.26 | $-0.11 | $-0.09 | $-0.18 | $0.24 | $-0.12 | $0.03 | $-0.04 | $0.06 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.56% | 977.18% | 1.42% | 1.74% | 0.02% | 2.98% | 4.56% | 3.11% | 0.88% | 0.80% | -0.64% | -1.12% | -0.71% | 17.32% | 1.42% | 14.49% | -2.19% | 5.26% |
According to 6 Wall Street analysts, BioMarin Pharmaceutical's projected average Quarter EPS for Mar 24 is $0.31, with a low estimate of $0.29 and a high estimate of $0.32. This represents a 183.48% increase compared to BMRN previous annual EPS of $0.11 (Dec 23).
BioMarin Pharmaceutical Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| ARWR | Arrowhead Pharmaceuticals | $21.49 | $45.38 | 111.17% | Buy |
| APLS | Apellis Pharmaceuticals | $37.62 | $75.81 | 101.52% | Buy |
| LQDA | Liquidia | $9.80 | $17.17 | 75.20% | Buy |
| MREO | Mereo BioPharma Group | $4.28 | $6.75 | 57.71% | Buy |
| LEGN | Legend Biotech | $50.31 | $78.78 | 56.59% | Buy |
| TECH | Bio-Techne | $74.67 | $99.21 | 32.86% | Buy |
| BMRN | BioMarin Pharmaceutical | $84.90 | $111.41 | 31.22% | Buy |
| INCY | Incyte | $63.56 | $81.00 | 27.44% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.62 | $3.33 | 27.10% | Buy |
| IONS | Ionis Pharmaceuticals | $42.19 | $50.84 | 20.50% | Buy |
| BPMC | Blueprint Medicines | $88.90 | $101.50 | 14.17% | Buy |
| PCVX | Vaxcyte | $116.00 | $124.14 | 7.02% | Buy |
| EXEL | Exelixis | $26.46 | $28.00 | 5.82% | Buy |
| AGIO | Agios Pharmaceuticals | $46.69 | $47.50 | 1.73% | Buy |
| ALNY | Alnylam Pharmaceuticals | $265.27 | $250.16 | -5.70% | Buy |
| HALO | Halozyme Therapeutics | $62.30 | $56.86 | -8.73% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |
BMRN Forecast FAQ
Is BioMarin Pharmaceutical a good buy?
Yes, according to 17 Wall Street analysts, BioMarin Pharmaceutical (BMRN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 10 'Buy' recommendations, accounting for 58.82% of BMRN's total ratings.
What is BMRN's price target?
BioMarin Pharmaceutical (BMRN) average price target is $111.41 with a range of $72 to $135, implying a 31.22% from its last price of $84.9. The data is based on 17 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will BioMarin Pharmaceutical stock go up soon?
According to Wall Street analysts' prediction for BMRN stock, the company can go up by 31.22% (from the last price of $84.9 to the average price target of $111.41), up by 59.01% based on the highest stock price target, and down by -15.19% based on the lowest stock price target.
Can BioMarin Pharmaceutical stock reach $130?
BMRN's highest twelve months analyst stock price target of $135 supports the claim that BioMarin Pharmaceutical can reach $130 in the near future.
What is BioMarin Pharmaceutical's current price target trend?
5 Wall Street analysts forecast a $109.8 price target for BioMarin Pharmaceutical (BMRN) this month, up 29.33% from its last price of $84.9. Compared to the last 3 and 12 months, the average price target increased by 28.78% and increased by 23.17%, respectively.
What are BioMarin Pharmaceutical's analysts' financial forecasts?
BioMarin Pharmaceutical's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $3.1B (high $3.19B, low $2.96B), average EBITDA is $120.42M (high $123.79M, low $114.96M), average net income is $549.64M (high $569.61M, low $517.2M), average SG&A $1.24B (high $1.28B, low $1.19B), and average EPS is $2.74 (high $2.84, low $2.58). BMRN's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $3.58B (high $3.68B, low $3.41B), average EBITDA is $138.89M (high $142.77M, low $132.59M), average net income is $0 (high $0, low $0), average SG&A $1.43B (high $1.47B, low $1.37B), and average EPS is $0 (high $0, low $0).
Did the BMRN's actual financial results beat the analysts' financial forecasts?
Based on BioMarin Pharmaceutical's last annual report (Dec 2023), the company's revenue was $2.42T, beating the average analysts forecast of $2.41B by 100355.98%. Apple's EBITDA was $158.1B, beating the average prediction of $308.73M by 51109.29%. The company's net income was $167.64B, beating the average estimation of $299.34M by 55905.12%. Apple's SG&A was $937.29B, beating the average forecast of $1.02B by 92203.87%. Lastly, the company's EPS was $0.87, beating the average prediction of $0.783 by 11.09%. In terms of the last quarterly report (Dec 2023), BioMarin Pharmaceutical's revenue was $646.21B, beating the average analysts' forecast of $638.82M by 101056.56%. The company's EBITDA was $14.22B, beating the average prediction of $24.81M by 57204.63%. BioMarin Pharmaceutical's net income was $20.38B, beating the average estimation of $39.53M by 51441.09%. The company's SG&A was $275.02B, beating the average forecast of $255.84M by 107397.01%. Lastly, the company's EPS was $0.11, missing the average prediction of $0.197 by -44.21%